NICE recommends the use of Opdivo in resected oesophageal or gastro-oesophageal junction cancer.
In July 2021 Opdivo was cleared as an adjuvant treatment of completely resected oesophageal or GEJ cancer in adults who have residual disease following neoadjuvant chemoradiotherapy.
The new recommendation is based on data showing that Opdivo increases the time patients are able to live without their cancer returning compared to placebo, in patients who had residual disease after chemo or radiotherapy and after surgical intervention.
Related news and insights
UCB announced that the European Commission (EC) has granted a marketing authorization for Zilbrysq (zilucoplan) as an add-on to standard therapy for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive
The FDA has received reports of T-cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA- or CD19-directed autologous CAR T cell immunotherapies. Reports were received from clinical trials and/or postmarketing adverse event (AE) data sources.
Pfizer Inc. announced topline data from the Phase II clinical trial (NCT04707313) investigating its oral Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate, danuglipron (PF-06882961), in adults with obesity and without type 2 diabetes.